<\/p>\n
Cosart<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 25 mg losartan tablet<\/strong> from Abbott Healthcare — an angiotensin II receptor blocker (ARB)<\/strong>. ARBs are first-line antihypertensive therapy<\/strong> alongside ACE inhibitors, CCBs, and thiazides per NICE, AHA\/ACC, and ESC\/ESH guidelines — and are the preferred alternative when an ACE inhibitor is not tolerated<\/strong> (usually because of the dry cough, which affects up to 20% of ACE-inhibitor users). The first ARB approved for clinical use (DuPont Merck 1995, as Cozaar<\/strong>) — the reference agent of the class. Losartan is a prodrug activated by CYP2C9 and CYP3A4 to its active metabolite E-3174 (EXP-3174). The parent drug has half-life ~2 hours; the active metabolite has half-life 6-9 hours. Typical hypertension dose: start 50 mg once daily (25 mg in elderly, volume-depleted, or hepatic impairment), target 50-100 mg once daily (divided into 50 mg twice daily in some patients)<\/strong>. Losartan has a modest uricosuric effect<\/strong> — it lowers serum uric acid (unique among ARBs; other ARBs are uric acid neutral or mildly raise it). Particularly useful in patients with hypertension AND gout or hyperuricaemia<\/strong>, where HCTZ-based combinations are problematic. Absolutely contraindicated in pregnancy<\/strong> (all trimesters — same teratogenic profile as ACE inhibitors: fetal renal agenesis, oligohydramnios, pulmonary hypoplasia), bilateral renal artery stenosis<\/strong>, \u03ba\u03b1\u03b9 concurrent sacubitril\/valsartan or aliskiren<\/strong>. Monitor potassium and creatinine.<\/p>\n<\/div>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n \u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n Cosart is an oral 25 mg losartan tablet from Abbott Healthcare, supplied in 30-180 tablets. The first ARB approved for clinical use (DuPont Merck 1995, as Cozaar<\/strong>) — the reference agent of the class. Losartan is a prodrug activated by CYP2C9 and CYP3A4 to its active metabolite E-3174 (EXP-3174). The parent drug has half-life ~2 hours; the active metabolite has half-life 6-9 hours.<\/p>\n ARBs block the angiotensin II type 1 (AT1<\/sub>) receptor<\/strong> directly, preventing angiotensin II from binding and exerting its vasoconstrictor and aldosterone-releasing effects. This is one receptor downstream of where ACE inhibitors act (which block angiotensin II formation) and produces equivalent clinical effects:<\/p>\n Clinical consequence of this mechanism: ARBs achieve equivalent BP control to ACE inhibitors with lower rates of cough (0-3% vs 20% for ACEi) and angioedema (roughly 30-50% lower than ACEi, though not zero).<\/p>\n Pivotal trial evidence:<\/strong> LIFE trial (2002)<\/strong> — losartan-based therapy reduced stroke, CV death, and MI by 13% vs atenolol-based therapy in hypertension with left-ventricular hypertrophy, establishing the modern preference for ARBs over older beta-blockers in HTN. RENAAL + IDNT<\/strong> — renoprotection in diabetic nephropathy. HEAAL<\/strong> — high-dose losartan (150 mg) vs low-dose (50 mg) in HF-REF; high-dose reduced hospitalisation.<\/p>\n Hypertension:<\/strong><\/p>\n Heart failure:<\/strong> Start 12.5 mg once daily, titrate weekly to 50-150 mg once daily (HEAAL target)<\/p>\n Administration:<\/strong> once daily, with or without food. Take at the same time each day for stable BP control.<\/p>\n \u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7:<\/strong><\/p>\n Discontinuation:<\/strong> no withdrawal syndrome; however, abrupt stop causes BP rebound over days. Taper over 1-2 weeks when stopping.<\/p>\n Common (>1%, usually mild):<\/strong><\/p>\n \u03a3\u03c0\u03ac\u03bd\u03b9\u03b1 \u03b1\u03bb\u03bb\u03ac \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac:<\/strong><\/p>\n Breastfeeding:<\/strong> avoid in the first weeks after delivery of a premature infant. Long-term use in established breastfeeding is generally considered acceptable given low milk transfer, but alternative antihypertensives (propranolol, nifedipine) are preferred when possible.<\/p>\n\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
What Is Cosart?<\/h2>\n
How Losartan Lowers Blood Pressure<\/h2>\n
\n
Approved and Evidence-Based Uses<\/h2>\n
\n
Cosart Dosage<\/h2>\n
\n
\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n
\n
\n
\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n
\n
\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n
\n
ARB Class at a Glance<\/h2>\n